Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDUFA Public Forum Previews Hill Debate; Safety, Critical Path Emphasized

Executive Summary

With the Prescription Drug User Fee Act moving towards reauthorization, a public forum on Feb. 16 hinted at how that debate may play out on Capitol Hill. At the meeting sponsored by FDA, outside groups voiced concerns about the agency's proposal for the PDUFA program and made their case for how FDA should organize and spend requested funding
Advertisement

Related Content

PDUFA Negotiations Would Add Patient, Consumer Reps Under House Bill
PDUFA Negotiations Would Add Patient, Consumer Reps Under House Bill
DTC Review Will Cost Industry $83,000 Per Ad Under FDA’s Final PDUFA Plan
DTC Review Will Cost Industry $83,000 Per Ad Under FDA’s Final PDUFA Plan
Ketek Superiority Trials May Hold Key To Sales After Safety Relabeling
“Critical Path” Is On The Road Forward; FDA Reports Industry Activity Is High
User Fee Deal For Ad Review Funds Stems From PhRMA DTC Principles
Enzi/Kennedy Drug Safety Bill Will Expand FDA’s Oversight Armamentarium
Advertisement
UsernamePublicRestriction

Register

PS048082

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel